Agilent Technologies Inc (NYSE:A) CEO Michael R. Mcmullen sold 21,850 shares of the stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $72.50, for a total transaction of $1,584,125.00. Following the completion of the sale, the chief executive officer now directly owns 324,687 shares in the company, valued at $23,539,807.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Agilent Technologies Inc (NYSE A) traded up $0.13 during midday trading on Friday, reaching $72.19. 1,828,300 shares of the company’s stock were exchanged, compared to its average volume of 1,846,967. Agilent Technologies Inc has a twelve month low of $47.05 and a twelve month high of $72.50. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.30 and a quick ratio of 2.85. The company has a market capitalization of $23,450.00, a PE ratio of 34.54, a P/E/G ratio of 2.18 and a beta of 1.28.
Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.95%. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the business earned $0.59 earnings per share. The business’s quarterly revenue was up 7.0% on a year-over-year basis. sell-side analysts forecast that Agilent Technologies Inc will post 2.58 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Agilent Technologies by 3.0% in the second quarter. Vanguard Group Inc. now owns 22,093,669 shares of the medical research company’s stock worth $1,310,374,000 after purchasing an additional 637,698 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Agilent Technologies by 8.2% in the third quarter. Victory Capital Management Inc. now owns 3,330,488 shares of the medical research company’s stock worth $213,817,000 after purchasing an additional 253,250 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Agilent Technologies by 27.6% in the third quarter. Wells Fargo & Company MN now owns 2,184,502 shares of the medical research company’s stock worth $140,244,000 after purchasing an additional 473,047 shares during the last quarter. Impax Asset Management LTD grew its holdings in shares of Agilent Technologies by 14.9% in the third quarter. Impax Asset Management LTD now owns 2,106,322 shares of the medical research company’s stock worth $135,226,000 after purchasing an additional 272,571 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Agilent Technologies by 2.9% in the third quarter. Legal & General Group Plc now owns 1,690,240 shares of the medical research company’s stock worth $108,512,000 after purchasing an additional 46,962 shares during the last quarter.
A number of equities research analysts have recently issued reports on the stock. Robert W. Baird reissued a “buy” rating and issued a $76.00 price target on shares of Agilent Technologies in a report on Thursday. Barclays reaffirmed a “buy” rating and issued a $74.00 target price on shares of Agilent Technologies in a research note on Monday, January 8th. Evercore ISI began coverage on shares of Agilent Technologies in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $75.00 target price on the stock. ValuEngine downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Cowen reaffirmed a “hold” rating and issued a $70.00 target price on shares of Agilent Technologies in a research note on Wednesday, November 22nd. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $69.25.
COPYRIGHT VIOLATION WARNING: “Agilent Technologies Inc (A) CEO Michael R. Mcmullen Sells 21,850 Shares” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/19/agilent-technologies-inc-a-ceo-michael-r-mcmullen-sells-21850-shares.html.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.